{
  "pmcid": "6771829",
  "sha256": "8bf382e5ab93d10a9284575eecd5e8ac650d2b70bde1b1c7282682d70c12d51c",
  "timestamp_utc": "2025-11-09T16:10:35.114503+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.04068656716418,
    "reading_ease": 33.38988557213932,
    "word_count": 268
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "The UK Medical Research Council ST03 trial compared perioperative epirubicin, cisplatin and capecitabine (ECX) chemotherapy with or without bevacizumab (B) in gastric and oesophagogastric junctional cancer."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Of 1063 patients randomized, 895 (84·2 per cent) underwent resection; surgical details were available for 880 (98·3 per cent)."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "The UK Medical Research Council ST03 trial compared perioperative epirubicin, cisplatin and capecitabine (ECX) chemotherapy with or without bevacizumab (B) in gastric and oesophagogastric junctional cancer."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Of 1063 patients randomized, 895 (84·2 per cent) underwent resection; surgical details were available for 880 (98·3 per cent)."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Postoperative assessment data were available for 873 patients; complications occurred in 458 (52·5 per cent) overall."
      },
      "Result_Outcome": {
        "score": 1,
        "evidence": "No difference in survival was noted between the arms of the trial."
      },
      "Harms": {
        "score": 1,
        "evidence": "Complications occurred in 458 (52·5 per cent) overall, of whom 71 (8·1 per cent) developed complications deemed to be life‐threatening by the responsible clinician."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Registration number: NCT00450203 ( http://www.clinicaltrials.gov )."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 9,
    "max_score": 25
  }
}